Promise Proteomics

Executive Summary

Promise Proteomics is a French private company founded in 2016, specializing in quantitative assays for therapeutic monoclonal antibodies (mAbs). Its flagship product, the mAbXmise quantification kit, enables monitoring of mAb concentrations in patient plasma or serum, intended to assist healthcare professionals in therapy management. Operating at the intersection of proteomics and oncology, the company addresses a growing need for precision dosing in mAb treatments, as therapeutic drug monitoring becomes increasingly critical for optimizing efficacy and safety. Despite limited public financial data and a modest profile, Promise Proteomics occupies a niche with potential for adoption in clinical labs. The company's focus on companion diagnostics aligns with trends toward personalized medicine, positioning it for growth if it can secure regulatory approvals and commercial partnerships.

Upcoming Catalysts (preview)

• Q3 2026Regulatory Approval (CE-IVD or CE-marking) for mAbXmise Kit60% success
• Q4 2026Commercial Partnership with a Major Pharmaceutical Company40% success
• Q1 2027Expansion of Product Line to New Therapeutic mAbs50% success